Log In Sign Up

Trading

Trading

Browse Companies

Data

Data

IPO Stock Tracker

Solutions

Solutions

For Institutions

For Shareholders

Insights

Insights

Popular Topics

Buying Pre-IPO Shares

Selling Pre-IPO Shares

Private Market Reports

Private Market Data & Analytics

About

About

Investor Relations

People & Culture

4D Molecular Therapeutics (4DMT) Stock

4dmoleculartherapeutics.comHealthcareFounded: 2013Funding to Date: $109MM

4DMT is a biotechnology company focused on pioneering the development of precision gene therapies based on proprietary AAV vectors.

Learn more about 4D Molecular Therapeutics (4DMT) IPO

Overview Financings Valuation

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for 4D Molecular Therapeutics (4DMT).

Register Today

Team

Management Team

David Kirn MD

Chief Executive Officer, Chairman & Co-Founder

Melissa Kotterman Ph.D

Vice President, Discovery & Engineering & Co-Founder

August Moretti JD

Chief Financial Officer

Fred Kamal Ph.D

Chief Technology Officer

Peter Francis MD

Chief Medical Officer

Theresa Janke

Co-Founder & Chief Operating Officer

Leisa Johnson

Vice President, Pre-Clinical R&D, Pharmacology & Toxicology Program Leader, Lung Therapeutic Area

David Schaffer Ph.D

Co-Founder, Chief Scientific Advisor & Board Member

Board Members

Charles Theuer MD

Self

Deborah Marshall JD

Sidley Austin

Margi McLaughlin Ph.D

Self

David Schaeffer Ph.D

Hoyoung Huh Ph.D

Self

David Kirn MD

4DMT

Jacob Chacko MD

Self

Tony Yao Ph.D

ArrowMark Partners

Other companies like 4D Molecular Therapeutics (4DMT) in the Healthcare sector

Sector

Last Round Est. Valuation

$2.15B

Colossal Biosciences

Sector

Sector

Last Round Est. Valuation

$3.67B

Sector

Last Round Est. Valuation

$400.53MM

Sector

Last Round Est. Valuation

$4.26B

Sector

Sector

Mammoth Biosciences

Sector

Last Round Est. Valuation

$1.08B

Precision Neuroscience

Sector

Frequently Asked Questions